(2S,3R,4E,6E)-N-[(E)-1-[[(1S,4R,10R,13Z,16S,27R,31S,32S,35R)-10-[(1S)-3-amino-1-hydroxy-3-oxopropyl]-4-(3-amino-3-oxopropyl)-13-ethylidene-21-hydroxy-35-[(1R)-1-hydroxyethyl]-27-methoxy-31-methyl-3,6,9,12,15,25,29,33,36-nonaoxo-2,5,8,11,14,24,26,30,34,37-decazatetracyclo[14.12.9.118,22.023,27]octatriaconta-18(38),19,21,23-tetraen-32-yl]amino]-1-oxobut-2-en-2-yl]-2-hydroxy-3-[(2R,3S,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxytetradeca-4,6-dienamide
| Internal ID | a318fa39-9172-409c-85bc-e67c6f368dec |
| Taxonomy | Organic acids and derivatives > Carboxylic acids and derivatives > Amino acids, peptides, and analogues > Peptides > Cyclic peptides |
| IUPAC Name | (2S,3R,4E,6E)-N-[(E)-1-[[(1S,4R,10R,13Z,16S,27R,31S,32S,35R)-10-[(1S)-3-amino-1-hydroxy-3-oxopropyl]-4-(3-amino-3-oxopropyl)-13-ethylidene-21-hydroxy-35-[(1R)-1-hydroxyethyl]-27-methoxy-31-methyl-3,6,9,12,15,25,29,33,36-nonaoxo-2,5,8,11,14,24,26,30,34,37-decazatetracyclo[14.12.9.118,22.023,27]octatriaconta-18(38),19,21,23-tetraen-32-yl]amino]-1-oxobut-2-en-2-yl]-2-hydroxy-3-[(2R,3S,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxytetradeca-4,6-dienamide |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C63H90N14O23/c1-7-10-11-12-13-14-15-16-17-18-41(100-61-50(87)48(85)40(81)28-99-61)49(86)60(96)70-34(9-3)52(88)73-45-29(4)67-56(92)37-26-63(98-6)51(76-62(97)77-63)32-23-31(19-21-38(32)79)24-36(71-59(95)46(30(5)78)74-58(45)94)55(91)69-33(8-2)53(89)75-47(39(80)25-43(65)83)57(93)66-27-44(84)68-35(54(90)72-37)20-22-42(64)82/h8-9,15-19,21,23,29-30,35-37,39-41,45-50,61,78-81,85-87H,7,10-14,20,22,24-28H2,1-6H3,(H2,64,82)(H2,65,83)(H,66,93)(H,67,92)(H,68,84)(H,69,91)(H,70,96)(H,71,95)(H,72,90)(H,73,88)(H,74,94)(H,75,89)(H,77,97)/b16-15+,18-17+,33-8-,34-9+/t29-,30+,35+,36-,37-,39-,40+,41+,45-,46+,47+,48-,49-,50-,61+,63+/m0/s1 |
| InChI Key | CZQRZTKBULVTIS-JUOPYZOASA-N |
| Popularity | 2 references in papers |
| Molecular Formula | C63H90N14O23 |
| Molecular Weight | 1411.50 g/mol |
| Exact Mass | 1410.63032517 g/mol |
| Topological Polar Surface Area (TPSA) | 588.00 Ų |
| XlogP | -3.30 |
| Atomic LogP (AlogP) | -6.68 |
| H-Bond Acceptor | 23 |
| H-Bond Donor | 20 |
| Rotatable Bonds | 23 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.6723 | 67.23% |
| Caco-2 | - | 0.8638 | 86.38% |
| Blood Brain Barrier | - | 0.8750 | 87.50% |
| Human oral bioavailability | - | 0.8000 | 80.00% |
| Subcellular localzation | Mitochondria | 0.4843 | 48.43% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.7931 | 79.31% |
| OATP1B3 inhibitior | + | 0.9312 | 93.12% |
| MATE1 inhibitior | - | 0.9200 | 92.00% |
| OCT2 inhibitior | - | 0.8750 | 87.50% |
| BSEP inhibitior | + | 0.9617 | 96.17% |
| P-glycoprotein inhibitior | + | 0.7420 | 74.20% |
| P-glycoprotein substrate | + | 0.8774 | 87.74% |
| CYP3A4 substrate | + | 0.7601 | 76.01% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8600 | 86.00% |
| CYP3A4 inhibition | + | 0.5714 | 57.14% |
| CYP2C9 inhibition | - | 0.8032 | 80.32% |
| CYP2C19 inhibition | - | 0.8234 | 82.34% |
| CYP2D6 inhibition | - | 0.8749 | 87.49% |
| CYP1A2 inhibition | - | 0.8153 | 81.53% |
| CYP2C8 inhibition | + | 0.8713 | 87.13% |
| CYP inhibitory promiscuity | - | 0.9123 | 91.23% |
| UGT catelyzed | - | 0.5000 | 50.00% |
| Carcinogenicity (binary) | - | 0.8900 | 89.00% |
| Carcinogenicity (trinary) | Non-required | 0.5844 | 58.44% |
| Eye corrosion | - | 0.9826 | 98.26% |
| Eye irritation | - | 0.8957 | 89.57% |
| Skin irritation | - | 0.7528 | 75.28% |
| Skin corrosion | - | 0.9209 | 92.09% |
| Ames mutagenesis | + | 0.5022 | 50.22% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7302 | 73.02% |
| Micronuclear | + | 0.7600 | 76.00% |
| Hepatotoxicity | + | 0.5038 | 50.38% |
| skin sensitisation | - | 0.8280 | 82.80% |
| Respiratory toxicity | + | 0.8000 | 80.00% |
| Reproductive toxicity | + | 0.9444 | 94.44% |
| Mitochondrial toxicity | + | 0.8375 | 83.75% |
| Nephrotoxicity | - | 0.6604 | 66.04% |
| Acute Oral Toxicity (c) | III | 0.5966 | 59.66% |
| Estrogen receptor binding | - | 0.5057 | 50.57% |
| Androgen receptor binding | + | 0.7689 | 76.89% |
| Thyroid receptor binding | + | 0.7766 | 77.66% |
| Glucocorticoid receptor binding | + | 0.8272 | 82.72% |
| Aromatase binding | + | 0.7867 | 78.67% |
| PPAR gamma | + | 0.7530 | 75.30% |
| Honey bee toxicity | - | 0.6159 | 61.59% |
| Biodegradation | - | 0.8250 | 82.50% |
| Crustacea aquatic toxicity | + | 0.6000 | 60.00% |
| Fish aquatic toxicity | + | 0.8991 | 89.91% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.94% | 91.11% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.69% | 98.95% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 99.48% | 96.09% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 98.55% | 99.17% |
| CHEMBL236 | P41143 | Delta opioid receptor | 98.45% | 99.35% |
| CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 97.98% | 96.38% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 97.60% | 92.88% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 97.12% | 90.71% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 97.09% | 94.45% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 95.96% | 91.03% |
| CHEMBL3038469 | P24941 | CDK2/Cyclin A | 94.72% | 91.38% |
| CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 94.61% | 85.14% |
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 94.45% | 83.82% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 93.41% | 95.89% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 93.28% | 97.09% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 93.21% | 95.93% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 93.18% | 89.00% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 92.69% | 94.75% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 92.20% | 96.90% |
| CHEMBL2001 | Q9H244 | Purinergic receptor P2Y12 | 90.96% | 96.00% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 89.55% | 95.71% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 89.36% | 93.10% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 89.35% | 91.24% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 89.34% | 93.56% |
| CHEMBL2850 | P49840 | Glycogen synthase kinase-3 alpha | 88.94% | 88.84% |
| CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 88.93% | 89.34% |
| CHEMBL1907600 | Q00535 | Cyclin-dependent kinase 5/CDK5 activator 1 | 88.77% | 93.03% |
| CHEMBL3830 | Q2M2I8 | Adaptor-associated kinase | 88.48% | 83.10% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 87.54% | 99.23% |
| CHEMBL225 | P28335 | Serotonin 2c (5-HT2c) receptor | 87.45% | 89.62% |
| CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 86.56% | 82.38% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 86.30% | 100.00% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 86.17% | 100.00% |
| CHEMBL1075162 | Q13304 | Uracil nucleotide/cysteinyl leukotriene receptor | 86.12% | 80.33% |
| CHEMBL3713062 | P10646 | Tissue factor pathway inhibitor | 86.09% | 97.33% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 85.63% | 95.83% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 85.36% | 86.33% |
| CHEMBL2535 | P11166 | Glucose transporter | 85.34% | 98.75% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 85.13% | 90.08% |
| CHEMBL3401 | O75469 | Pregnane X receptor | 84.38% | 94.73% |
| CHEMBL2335 | P42785 | Lysosomal Pro-X carboxypeptidase | 83.58% | 100.00% |
| CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 82.95% | 96.00% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 82.90% | 98.59% |
| CHEMBL3880 | P07900 | Heat shock protein HSP 90-alpha | 82.77% | 96.21% |
| CHEMBL5852 | Q96P65 | Pyroglutamylated RFamide peptide receptor | 82.58% | 85.00% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 82.53% | 95.50% |
| CHEMBL2996 | Q05655 | Protein kinase C delta | 82.46% | 97.79% |
| CHEMBL1951 | P21397 | Monoamine oxidase A | 81.67% | 91.49% |
| CHEMBL2007 | P16234 | Platelet-derived growth factor receptor alpha | 81.44% | 91.07% |
| CHEMBL2345 | P51812 | Ribosomal protein S6 kinase alpha 3 | 81.36% | 95.64% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 81.23% | 92.32% |
| CHEMBL4481 | P35228 | Nitric oxide synthase, inducible | 81.07% | 94.80% |
| CHEMBL4769 | O95749 | Geranylgeranyl pyrophosphate synthetase | 80.76% | 92.08% |
| CHEMBL5678 | P34947 | G protein-coupled receptor kinase 5 | 80.74% | 88.00% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 80.34% | 96.11% |
| CHEMBL2781 | P19634 | Sodium/hydrogen exchanger 1 | 80.22% | 90.24% |
| CHEMBL299 | P17252 | Protein kinase C alpha | 80.15% | 98.03% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 135433703 |
| LOTUS | LTS0089079 |
| wikiData | Q104973030 |